Table 2
From the following article
Chinese health biotech and the billion-patient market
Sarah E Frew, Stephen M Sammut, Alysha F Shore, Joshua K Ramjist, Sara Al-Bader, Rahim Rezaie, Abdallah S Daar & Peter A Singer
Nature Biotechnology 26, 37 - 53 (2008)
doi:10.1038/nbt0108-37
Table 2. IP portfolios/marketing rights for companies interviewed
| Company name | Patents filed or issued |
|---|---|
| Beijing Wantai Biological Pharmacy Enterprise | Patent Cooperation Treaty (PCT) patent for a HEV recombinant antigen vaccine, describing the function of the protein of the virus, the epitopes/antigens and antibodies. |
| Bio-Bridge Science | US and Chinese patents issued on core vaccine technology (papilloma pseudovirus); patent filed in Japan. |
| CapitalBio | Filed over 98 patents in all, with 54 patents issued for methods, devices, invention (12 US issued patents; 1 patent issued in Japan; 1 patent issued in Taiwan; 1 patent issued in Hong Kong; and 39 patents issued in China). |
| FusoGen Pharmaceuticals | US, Singaporean, Russian and Chinese patents issued on HIV fusion inhibitor (sifuvirtide). Patents filed in Europe and Japan. |
| GeneScience Pharmaceuticals | Of three PCT filings, one on IFN- for HBV in suppository formulation has been granted. One Chinese patent issued on core E. coli secretion technology, and six other Chinese patents filed, (including one on three on various formulations (oral, suppository and long-acting) of human growth hormone). |
| HD Biosciences | More than ten Chinese patents filed, including for the extraction and preparation of lycorine as an anti-SARS product and for the use of the compound Daphne to lower low-density lipoprotein. |
| Shanghai Fudan-Yueda Bio-Tech | Patents issued in the US and one in China for the Immunogenic Complex Therapeutic Vaccine for Hepatitis B. Another six patents filed in China for Hepatitis B surface antigen-antibody complex used to elicit immune response for patients with low response level to Hepatitis B vaccines, genetic testing for Hepatitis B drug resistance, immune responses to Hepatitis DNA vaccine injected by Hepatitis B Virus gene guns, and a SARS testing kit. |
| Shanghai Genomics | Over 26 patents filed, five under PCT and the rest within China. One Chinese patent has been issued for use of the small-molecule new chemical entity F351, which has been developed as a non-steroid anti-fibrosis drug that has shown strong efficacy for treating a broad range of fibrosis diseases, especially in the liver. The additional patents cover new uses of F351 or new drug targets. |
| Shanghai Genon Bio-Engineering | Eighteen patents filed in China, eight issued for recombinant human lysozyme and lactoferrin. |
| Shanghai Huaguan Biochip | Four patents filed in China for protein chips that detect HCV, 160S rDNA-related diseases and Gastritis, and for nanometer particles to detect DNA mutations. |
| Shanghai Sunway Biotech | Eleven international patent applications filed (including exclusive worldwide patent for the EIB-B55KD adenovirus), with six issued; ten patent applications filed in China with one issued. |
| Shenzhen Beike Biotechnologies | Two patents filed in China related to preparation of amniotic membrane of mesenchymal stem cells. |
| Shenzhen Chipscreen Biosciences | Five composition of matter patents filed in the United States, three issued, including patents covering two clinical stage compounds, Chiglitazar and Chidamide. 4 PCT patents filed for the preparation and pharmaceutical use of retinoic acid analogs, for noncyclic 1,3-dicarbonyl compounds as dual PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity, for substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity, and for histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and antiproliferation activity. Thirteen patents filed in China, six issued. Four patents filed in Taiwan and Hong Kong, one issued. Three data-mining/analysis software copyrights issued. |
| SiBiono GeneTech | Four international patents filed through PCT for Gendicine. Seven patents filed for Gendicine in China. Of those, product invention and manufacture technology have been issued in China; the other five are pending. |
| Sinocells Biotech | Seven patents filed and two issued in China relating to somatic stem cells. |
| SinoGenoMax | 40 patents filed, some PCT (US, Europe, Australia or Japan), some in China. The majority are gene patents, specifically related to cancer—others are technology based. |
| Sinovac Biotech | One Chinese patent issued and one patent application withdrawn, both relating to SARS vaccine technology. |
| Tianjin SinoBiotech | Two US patent applications, one PCT application and three Chinese patent applications filed related to gene-based drug development. One Chinese patent has been issued for the use of recombinant human serum albumin fusion protein to stimulate cell proliferation. |